KORRO BIO INC (KRRO)
Health Care · Oligonucleotide therapeutics / genetic disease treatment · NASDAQ
Korro Bio is a clinical-stage biotechnology company developing genetic medicines via a proprietary oligonucleotide platform, currently focused on treating alpha-1 antitrypsin deficiency.
What KORRO BIO INC does
Korro Bio, Inc. is a biopharmaceutical company that researches, develops, and aims to commercialize oligonucleotide-based therapeutics using GalNAc-conjugation technology. The company focuses on treating genetic diseases and protein misfolding disorders through its lead development program, KRRO-121 for alpha-1 antitrypsin deficiency (AATD), with plans to submit a regulatory application in the second half of 2026. Korro Bio operates through a combination of Legacy Korro Bio Ops, Inc. (acquired via business combination in November 2023) and its predecessor Frequency Therapeutics, employing oligonucleotide research and next-generation therapeutic approaches to address serious unmet medical needs.
Themes: Oligonucleotide therapeutics, Genetic diseases / rare genetic disorders, Alpha-1 antitrypsin deficiency (AATD), GalNAc-conjugation technology, Protein misfolding disorders
Fundamentals
- Price$13.18 as of 2026-08-21 close
- Market cap$194M as of 2026-08-21
- 1-year return-35.9% 2025-08-21 close $20.55 → 2026-08-21 close $13.18
- P/En/a negative earnings
- Net margin-1834.5% as of 2026-08-24
- Gross margin+44.7% as of 2026-08-24
- ROE-114.3% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)-62.1% as of 2026-08-24
- Beta3.11 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How KRRO compares in its sector
- net profit marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- operating marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- gross marginbottom 25% 384 covered Health Care peers, as of 2026-08-24
- return on equitybottom 25% 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How KORRO BIO INC looks technically
KORRO BIO INC (KRRO) is trading 5.3% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 1 trading day ago — a "golden cross", a bullish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 23 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 56, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 3 trading days ago. It is 76.4% below its highest point of the past year. Trading volume is unusually light — only about 33% of its 30-day average.
Trend
9
| Distance from the 200-day | it is trading 5.3% above its 200-day average, the long-term trend line — a longer-term uptrend | +5.3% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $12.54 | $12.54 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $12.51 | $12.51 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 10 calendar days ago — the swings before that are what the structure reading is measured on | 10 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes above 14. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible downward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 1 trading day ago — a "golden cross", a bullish long-term signal | 1 session |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 5.3% above | +5.3% |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 23 (a reading of 25+ marks a strong trend) | 22.5 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 56, neither overbought (above 70) nor oversold (below 30) | 55.6 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($10.53 to $14.19) — its "stochastic" reading is 73 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 72.5 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 12 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $55.89 | $55.89 |
|---|---|---|
| From the 52-week high | it is 76.4% below its 52-week high (its highest price of the past year) | -76.4% |
| Above the 52-week low | it is 153.3% above its 52-week low (its lowest price of the past year) | +153.3% |
| Below the 52-week high | it is 76.4% below its highest point of the past year | 76.4% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day high about 33 trading days ago | 33 sessions |
| All-time high | its highest closing price on record is $2918.50 (set on 2021-02-08) | $2918.50 |
| Given back of the 52-week move | over the past year its closes ranged ($5.28 to $51.36), and it has recovered roughly a quarter of its fall from last year’s high — 17% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $33.76 to $35.23. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 17.1% |
| From the all-time high | it is 99.5% below its all-time high | -99.5% |
| Nearest price level | it is trading 1.4% below a resistance level at $13.37 — a price it turned at twice since 2025-05-14, most recently on 2025-08-01. Since 2024-08-21 it has 2 such levels below the current price and 10 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +1.4% |
| All-time low | its lowest closing price on record is $5.20 (set on 2025-12-02) | $5.20 |
| Above the all-time low | it is 153.3% above its all-time low | +153.3% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 70th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.8622 between its high and its low — about 6.5% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.8622 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $9.62 and $14.80 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $9.62 – $12.21 – $14.80 |
| Typical daily range (% of price) | its price moves about 6.5% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.5% |
| Stretch from the 200-day average | it is trading 0.8 daily ranges above its 200-day average price (5.3% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 0.8 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 33% of its 30-day average | 0.33× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 4 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 4 sessions ago |
|---|---|---|
| Since a hammer | 3 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 3 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-08-21 0.5% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +0.5% |
|---|---|---|
| Gap filled | a 2.1% gap up opened on 2026-08-19 has been "filled" 1 session ago — price traded back through the level the gap left behind, and it took 1 session to close | 1 session ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 7.9 percentage points (the stock gained 10.2% while the market gained 2.3%) | +7.9% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 14.6 percentage points (the stock gained 17.7% while the market gained 3.1%) | +14.6% |
| vs market, 6 months | over the past 6 months this stock beat the market by 7.6 percentage points (the stock gained 18.6% while the market gained 11.1%) | +7.6% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 56.3 percentage points (the stock lost 35.9% while the market gained 20.5%) | -56.4% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 0 of the 9 technical signals we can compute for it are currently in a bearish state — these describe past price behaviour, not a forecast | 0 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is moderate, spanning 7.8% of the share price. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 9% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $12.05 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | +9.4% |
|---|---|---|
| Vs the average paid since it last reported | the price is sitting right on the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is roughly break-even. That average is $13.17 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | +0.1% |
Price levels it has turned at before
KRRO last closed at $13.18 on 2026-08-21. Since 2024-08-21 it has turned at 2 prices below its last close and 10 above; the 2 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $13.37 | Resistance | 1.4% above the last close | turned there twice · 2025-05-14 to 2025-08-01 |
| $13.93 | Resistance | 5.7% above the last close | turned there three times · 2026-05-01 to 2026-08-11 |
| $14.99 | Resistance | 13.8% above the last close | turned there four times · 2025-07-09 to 2026-06-24 |
| $10.27 | Support | 22.1% below the last close | turned there twice · 2025-06-02 to 2026-06-11 |
| $9.83 | Support | 25.4% below the last close | turned there twice · 2026-03-30 to 2026-07-31 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes above $14.00.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $4.63 and $8.21 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close above $14.00.
This reading has stood for 4 trading days, since 2026-08-18.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Recent golden cross (50-day crossed above 200-day) · Tested and reclaimed 200-day support · Pulled back from the 12-month high · Broke out to a new 20-day high · beating the market | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.36 mean, 1=Strong Buy…5=Strong Sell) — 10 analysts
- Mean price target$20.20 range $10.00 – $30.00; median $21.50
Analyst estimates, as of 2026-08-22. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for KRRO
- Consensus EPS estimate-$1.25 next reporting period, as of 2026-08-22
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical development risk: Success of KRRO-121 regulatory application submission and approval depends on achieving favorable clinical trial results; any failure in the Phase 2 or Phase 3 programs could materially impact the company's pipeline and valuation.","Collaboration uncertainty: Paused Novo Nordisk collaboration and dependency on securing future partnerships or licensing arrangements to fund operations and advance development programs.","Cash runway and operating losses: Significant unprofitability (negative net margin of -1834.48%) and cash consumption create substantial risk that the company may not have sufficient funds to reach meaningful clinical milestones or commercialization without additional financing."]
What changed in the latest 10-Q
AI-assisted comparison of KRRO's 10-Q filed 2026-05-07 against the prior one filed 2025-11-12.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing explicitly names the platform as 'OPERA' (oligonucleotide promoted editing of RNA) in the Overview section heading
- Newer filing adds detailed description of OPERA platform capabilities: 'sophisticated knowledge of transcription biology through ADAR proteins (Adenosine Deaminases Acting on RNA), machine learning optimization of oligonucleotides, linker chemistry expertise, along with use of a highly targeted tissue-specific delivery methodology'
- Newer filing adds: 'providing precise yet transient single base edits to produce therapeutic proteins with augmented activity versus its endogenous counterpart'
- Newer filing adds explanation of genetic mutation types: 'Genetic mutations, including single nucleotide variants, or SNVs, implicated in disease have been found to be diverse in nature and can affect the function of genes and their associated downstream biochemical pathways'
- Newer filing adds: 'the majority of SNVs implicated in complex diseases are due to modulation of gene function'
- Newer filing describes KRRO-121 as 'a potential first-in-class treatment for hyperammonemia'
- Newer filing adds: 'KRRO-121 is designed to generate a stabilized, de novo glutamine synthetase, or GS, protein, a critical enzyme involved in ammonia clearance'
- Newer filing adds: 'This synthetic rescue approach is designed to augment ammonia clearance in hyperammonemia-driven diseases such as UCDs and HE'
- Newer filing states: 'Our preclinical data support the potential for KRRO-121 to be a pan-UCD treatment'
- Newer filing adds: 'KRRO-121 may offer infrequent subcutaneous dosing'
- Newer filing adds: 'We anticipate a regulatory filing to enable commencement of a first-in-human trial in the second half of 2026'
- Newer filing adds: 'We are also advancing early-stage research and development programs highlighted by a GalNac-conjugated oligonucleotide for AATD'
- Newer filing adds: 'We are on track to announce our AATD development candidate in second quarter of 2026'
- Newer filing adds: 'plan to nominate a development candidate for a third GalNAc-conjugated program in the second half of 2026'
- Newer filing provides updated financial figures: 'raised approximately $501.0 million of aggregate gross proceeds'
- Newer filing provides updated net loss figures: '$19.6 million and $23.4 million for the three months ended March 31, 2026 and 2025, respectively'
- Newer filing provides updated accumulated deficit: '$403.5 million as of March 31, 2026'
- Newer filing reference changes from '2024 10-K' to '2025 10-K'
- Removed:
- Older filing describes company as 'clinical-stage biopharmaceutical company' whereas newer filing describes it as 'a biopharmaceutical company' (removed 'clinical-stage')
- Older filing states mission to 'discover, develop and commercialize' removed from newer filing Overview
- Older filing reference to 'Risk Factors' in 'Part I, Item 1A' changed to 'Part II, Item 1A' in newer filing
- Older filing detailed discussion of KRRO-110 clinical trial results, safety observations, pharmacodynamic/pharmacokinetic observations, and regulatory milestones entirely removed from newer filing
- Older filing states 'KRRO-110 did not reach projected levels of functional protein following a single administration' and pivoting to GalNAc delivery - this entire section removed
- Older filing reference to 'January 2025' announcement of KRRO-110 dosing removed
- Older filing detailed REWRITE clinical trial data removed
- Older filing description of preclinical modifications capabilities removed: 'single RNA changes can disrupt protein-protein interactions, prevent protein aggregation, selectively modulate ion channels and activate kinases'
- Older filing statement about 'unlock validated target classes' removed
- Older filing reference to 'current traditional drug modalities' removed
- Reworded:
- Older: 'clinical-stage biopharmaceutical company with a mission to discover, develop and commercialize a new class of genetic medicines based on editing RNA' changed to Newer: 'a biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA, or OPERA, platform to develop a new class of genetic medicines'
- Older: 'Our approach can be used to repair pathogenic single nucleotide variants' changed to Newer: 'By editing RNA to mimic a SNV, we believe we will be able to address unmet patient need'
- Older: 'oligonucleotide-based approach...with precedented delivery modalities...established regulatory pathways of approved oligonucleotide drugs' changed to Newer: 'oligonucleotide-based approach...with precedented delivery modalities...established regulatory pathways of approved oligonucleotide medicines'
- Older: 'we expect to bring our medicines to patients by leveraging our proprietary platform' changed to Newer: 'we expect to bring our medicines to patients by leveraging our proprietary OPERA platform'
- Older: 'RNA platform' changed to Newer: 'OPERA platform' in platform references
- Notes:
- The newer filing text appears truncated at the end, cutting off mid-sentence: 'As a resul'
- The older filing text also appears truncated at the end: 'We plan to nominate a development candidate for our GalNAc-conjug'
- Comparison is limited to the portions of text provided; full sections may contain additional changes not visible in the truncated versions
Risk Factors
- Added:
- Added definition: 'When we refer to our leads or lead candidates, we are referring to our oligonucleotides that we are researching for potential nomination as a development candidate. When we refer to our development candidates, we generally mean an oligonucleotide lead candidate that we have nominated for clinical development.' (filed 2026-05-07)
- Added forward-looking statement: 'the timing, progress, results, and cost of our KRRO-121 development program, including our ability to submit a regulatory application in the second half of 2026 for KRRO-121' (filed 2026-05-07)
- Added forward-looking statement: 'the timing of our expected announcement of a development candidate for our next-generation GalNAc-conjugated alpha-1 antitrypsin deficiency, or AATD, program' (filed 2026-05-07)
- Added risk factor bullet: 'If preclinical studies or clinical trials of any lead candidates or development candidates fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities or do not otherwise produce positive results (such as we experienced in the Phase 1/2a REWRITE clinical trial of KRRO-110 for AATD), we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of such development candidates.' (filed 2026-05-07)
- Removed:
- Removed definition paragraph beginning with 'In this Quarterly Report on Form 10-Q, when we refer to our leads or lead candidates...' (filed 2025-11-12)
- Removed forward-looking statement: 'the initiation, timing, progress, results, cost of and other statements regarding our research and development programs and our current and future preclinical studies and clinical trials, including the timing of the regulatory filing of first-in-human trial for KRRO-121 and nomination of a GalNAc Alpha-1 antitrypsin deficiency, or AATD, candidate, initiation and completion of studies or trials and related preparatory work, and the period during which the results of the trials will become available' (filed 2025-11-12)
- Removed forward-looking statement: 'the next steps for our Phase 1/2a REWRITE clinical trial of KRRO-110' (filed 2025-11-12)
- Removed risk factor bullet: 'We did not reach projected levels of protein in patients in our Phase 1/2a REWRITE clinical trial of KRRO-110 for AATD, and are pivoting to GalNAc delivery for AATD, and may experience delays in developing a potential treatment for AATD. We have not completed any clinical trials nor reported any clinical trial results for any of our proposed delivery methods or RNA editing approaches. Any favorable results we may have may not be predictive of results that may be observed in later preclinical studies or clinical trials.' (filed 2025-11-12)
- Removed reference to 'If we experience delays or difficulties in the enrollment of patients in clinical trials, or other delays in our clinical trials, our receipt of necessary regulator' (incomplete bullet point in 2025-11-12)
- Reworded:
- Changed 'express or implied statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding the future' to 'express or implied statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding the future' (no substantive change noted in this section)
- Changed forward-looking statements list from beginning with 'the initiation, timing, progress...' to beginning with 'the timing, progress, results...' for KRRO-121 (filed 2026-05-07 vs 2025-11-12)
- Changed 'product candidates' to 'development candidates' and 'lead candidates' in risk factor language (filed 2026-05-07)
- Changed 'the therapeutic and commercial potential of our product candidates' to 'the therapeutic and commercial potential of our development candidates' (filed 2026-05-07)
- Changed 'competing products and product candidates' to 'rival products and development candidates' (filed 2026-05-07)
- Notes:
- The newer filing appears truncated at 'We may not realize the anticipated be' suggesting the full Risk Factors section was not provided for comparison
- The older filing also appears truncated at 'If we experience delays or difficulties in the enrollment of patients in clinical trials, or other delays in our clinical trials, our receipt of necessary regulator' suggesting incomplete source text
- Page numbers changed between filings (Items 2-5 moved from pages 74-74 to pages 73-73), but this reflects reformatting rather than content changes
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 20 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 1 sell ($62917) — 1 selling insider
- Last 90 days0 buys · 20 sells ($4M) — 6 selling insiders
- Last 180 days0 buys · 20 sells ($4M) — 6 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-04. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about KRRO's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding KRRO as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 1,044,588
- Reported value $11,824,735
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
KRRO had 1,438,506 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
KRRO had 9.77% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 9.16 days to cover at the same settlement.
- Reported short interest (shares) 1,438,506
- Short interest (% of shares outstanding) 9.77%
- Prior settlement (shares) 1,459,180
- Reported change -1.42%
- Days to cover (reported) 9.16
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Alnylam Pharmaceuticals (ALNY)
- Ionis Pharmaceuticals (IONS)
- Arrowhead Pharmaceuticals (ARWR)
- Intellia Therapeutics (NTLA)
- CRISPR Therapeutics (CRSP)
- Beam Therapeutics (BEAM)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare KRRO vs…
Frequently asked questions
What does KORRO BIO INC (KRRO) do?
Korro Bio, Inc. is a biopharmaceutical company that researches, develops, and aims to commercialize oligonucleotide-based therapeutics using GalNAc-conjugation technology. The company focuses on treating genetic diseases and protein misfolding disorders through its lead development program, KRRO-121 for alpha-1 antitrypsin deficiency (AATD), with plans to submit a regulatory application in the second half of 2026. Korro Bio operates through a combination of Legacy Korro Bio Ops, Inc.
What sector is KORRO BIO INC (KRRO) in?
KORRO BIO INC (KRRO) is classified in the Health Care sector. Its industry is Oligonucleotide therapeutics / genetic disease treatment. It trades on NASDAQ.
Who are KORRO BIO INC's (KRRO) competitors?
Notable peers of KORRO BIO INC (KRRO) include Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals, Intellia Therapeutics and CRISPR Therapeutics. This peer set is informational only — not financial advice.
Is KORRO BIO INC (KRRO) overbought or oversold right now?
KORRO BIO INC (KRRO) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 56, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on KRRO come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.